Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Active-controlled Phase II Clinical Trial to Explore the Efficacy and Safety of Different Doses of TQC3927 Inhaled Powder in Patients With Chronic Obstructive Pulmonary Disease

NCT07633314 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07633314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07633314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Active-controlled Phase II Clinical Trial to Explore the Efficacy and Safety of Different Doses of TQC3927 Inhaled Powder in Patients With Chronic Obstructive Pulmonary Disease
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 2
Overall status
Suspended
Start date
December 31, 2026
Completion date
January 31, 2027
Enrollment
90 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease